Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
REGN logo REGN
Upturn stock ratingUpturn stock rating
REGN logo

Regeneron Pharmaceuticals Inc (REGN)

Upturn stock ratingUpturn stock rating
$521
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: REGN (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

25 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $737.92

Year Target Price $737.92

Analyst’s Price TargetsFor last 52 week
$737.92Target price
Low$476.49
Current$521
high$1207.86

Analysis of Past Performance

Type Stock
Historic Profit 10.59%
Avg. Invested days 56
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 56.25B USD
Price to earnings Ratio 13.24
1Y Target Price 727.21
Price to earnings Ratio 13.24
1Y Target Price 727.21
Volume (30-day avg) -
Beta 0.31
52 Weeks Range 476.49 - 1207.86
Updated Date 06/29/2025
52 Weeks Range 476.49 - 1207.86
Updated Date 06/29/2025
Dividends yield (FY) 0.68%
Basic EPS (TTM) 39.34

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 31.94%
Operating Margin (TTM) 19.94%

Management Effectiveness

Return on Assets (TTM) 6.91%
Return on Equity (TTM) 15.96%

Valuation

Trailing PE 13.24
Forward PE 14.24
Enterprise Value 50605423937
Price to Sales(TTM) 3.99
Enterprise Value 50605423937
Price to Sales(TTM) 3.99
Enterprise Value to Revenue 3.59
Enterprise Value to EBITDA 9.15
Shares Outstanding 106148000
Shares Floating 99889821
Shares Outstanding 106148000
Shares Floating 99889821
Percent Insiders 1.9
Percent Institutions 92.12

Analyst Ratings

Rating 4.28
Target Price 737.92
Buy 5
Strong Buy 14
Buy 5
Strong Buy 14
Hold 5
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Regeneron Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Regeneron Pharmaceuticals Inc. was founded in 1988 by Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D. Initially focused on neurotrophic factors, it evolved into a fully integrated biopharmaceutical company discovering, developing, and commercializing medicines for serious diseases.

business area logo Core Business Areas

  • Eye Disease: Develops and commercializes therapies for eye diseases, including macular degeneration and diabetic eye disease.
  • Allergic and Inflammatory Diseases: Develops and commercializes therapies for allergic conditions like asthma and atopic dermatitis.
  • Cancer: Develops therapies to treat different types of cancers.
  • Cardiovascular Disease: Develops therapies to treat cardiovascular diseases.
  • Infectious Diseases: Develops therapies to treat infectious diseases, including COVID-19.

leadership logo Leadership and Structure

Leonard S. Schleifer is the Founder, President, and CEO. George D. Yancopoulos is the Founder, President, and Chief Scientific Officer. The company has a typical corporate structure with various departments including R&D, Commercial, and Operations.

Top Products and Market Share

overview logo Key Offerings

  • Eylea (aflibercept): A VEGF inhibitor used to treat wet age-related macular degeneration, diabetic retinopathy, and other eye conditions. Competitors: Lucentis (Roche/Novartis), Beovu (Novartis). Eylea sales for Regeneron were $5.9 billion in 2023 (global excluding Bayer's share).
  • Dupixent (dupilumab): An antibody targeting IL-4 and IL-13 used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, developed and commercialized with Sanofi. Competitors: Adbry (LEO Pharma), Rinvoq (AbbVie), Cibinqo (Pfizer). Global Dupixent sales were $9.3 billion in 2023 (Regeneron recognizes their share of US profits).
  • Libtayo (cemiplimab): A PD-1 inhibitor used to treat certain types of skin cancer and lung cancer. Competitors: Keytruda (Merck), Opdivo (Bristol Myers Squibb). Libtayo global sales were $794 million in 2023.
  • Praluent (alirocumab): A PCSK9 inhibitor used to lower cholesterol, developed and commercialized with Sanofi. Competitors: Repatha (Amgen). Praluent Net Product Sales in US $212 million for 2023.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Key trends include personalized medicine, gene therapy, and increasing focus on chronic diseases.

Positioning

Regeneron is a leader in antibody-based therapies and has a strong R&D pipeline. Its competitive advantage lies in its proprietary VelociSuite technologies, which enable rapid discovery and development of new drugs.

Total Addressable Market (TAM)

The global pharmaceutical market is expected to reach over $1.7 trillion by 2027. Regeneron is positioned to capture a significant share of this TAM through its innovative products and strong R&D pipeline.

Upturn SWOT Analysis

Strengths

  • Strong R&D pipeline
  • Proprietary VelociSuite technologies
  • Successful commercialization of key products (Eylea, Dupixent)
  • Experienced management team
  • Strategic collaborations (e.g., Sanofi)

Weaknesses

  • Reliance on key products
  • Patent expiration risks
  • Competition from other pharmaceutical companies
  • Dependence on collaborations

Opportunities

  • Expansion into new therapeutic areas
  • Development of novel drug modalities
  • Acquisitions and partnerships
  • Growing global demand for pharmaceuticals

Threats

  • Regulatory hurdles
  • Pricing pressures
  • Generic competition
  • Clinical trial failures
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • ABBV
  • AMGN
  • BMY
  • SNY

Competitive Landscape

Regeneron faces intense competition from other large pharmaceutical companies. Its competitive advantage lies in its innovative technology and strong R&D pipeline. However, it is also vulnerable to patent expirations and generic competition.

Major Acquisitions

Decibel Therapeutics

  • Year: 2023
  • Acquisition Price (USD millions): 109
  • Strategic Rationale: Expand capabilities in hearing loss therapies.

Growth Trajectory and Initiatives

Historical Growth: Regeneron experienced rapid growth in the past decade, driven by the success of Eylea and Dupixent.

Future Projections: Analysts project continued growth for Regeneron, driven by new product launches and expansion of existing products into new indications. However, growth is expected to be slower than in the past.

Recent Initiatives: Regeneron is investing in new technologies and therapeutic areas, including gene therapy and oncology. The company is also expanding its global presence.

Summary

Regeneron is a strong biopharmaceutical company with a history of innovation and successful product launches. Its proprietary VelociSuite technologies provide a competitive advantage. However, the company faces challenges related to competition, patent expirations, and regulatory hurdles. It needs to continue investing in R&D and diversifying its product portfolio to sustain long-term growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Regeneron Pharmaceuticals Inc. Investor Relations
  • SEC Filings
  • Analyst Reports
  • Company Press Releases
  • Third Party Market Research Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Regeneron Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Tarrytown, NY, United States
IPO Launch date 1991-04-02
Co-Founder, President, CEO & Co-Chairman Dr. Leonard S. Schleifer M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 15158
Full time employees 15158

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.